Akebia Therapeutics, Inc. (AKBA) research
Akebia Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $0.86
- As of
Akebia Therapeutics, Inc. (AKBA): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-05.
As of . Source: SEC EDGAR filings for AKBA. Method and limitations.
Share the AKBA intelligence card
See the full AKBA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for AKBA on one page. Preview it with sample data, then open it live with a free account.
Preview the AKBA dossierActive signals for AKBA
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 54% of AKBA (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +711% to AKBA (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +445% to AKBA (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +88% to AKBA (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +1332% to AKBA (2026Q1)
FREE, NO ACCOUNT
Every signal on AKBA, as it fires
You are seeing 5 of 8 signals recorded on AKBA since 2026-06-16.
The five above landed across 2 days. The other 3 were recorded on 1 other days. 5 of the 8 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in AKBA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 00972D105 · 2026Q2 | $3.6M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 00972D105 · 2026Q2 | $2.8M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 00972D105 · 2026Q2 | $2M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 00972D105 · 2026Q2 | $1.4M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 00972D105 · 2026Q2 | $100K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, AKBA
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
AKBA against its peers
AKBA's operating margin of 9.9% ranks in the 81st percentile of 17 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-05-31.
| Metric | AKBA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 236M USD | 165M USD | 56 | 16 |
| Gross margin | n/a | 43.6% | n/a | 13 |
| Operating margin | 9.9% | -6.9% | 81 | 17 |
| Net margin | -2.3% | -23.6% | 81 | 17 |
| Return on equity | -16.4% | -23.6% | 57 | 14 |
Peers (19): ELTP, CRLBF, DERM, CRDL, TSNDF, CGC, ADCT, NIKA, VRNO, KMDA, TKNO, GRUSF, AAWH, CPIX, EOLS, VREOF, TLRY, AQST, BGM. Left out: LFCR (no annual filing), PHBI (period gap), ASRT (no annual filing), OGI (period gap), CTOR (no annual filing), EVO (period gap). Fiscal periods ending between 2025-09-30 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (AKBA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more AKBA signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to AKBAand get the insider, 13F, options, and confluence read in one view.